Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study Comparing Pembrolizumab with Intermittent/Short-term Dual MAPK Pathway Inhibition Plus Pembrolizumab in BRAFV600-mutant Melanoma (IMPemBra)
2015-003120-31Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in melanoma (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Safety and feasibility. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2015-003120-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003120-31.